Joseph Oliveto
Fortuna: 633 666 $ al 31/05/2026
Fortuna: 633 666 $ al 31/05/2026
Mr. Joseph G.
Oliveto is a President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. and a President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. He is on the Board of Directors at Milestone Pharmaceuticals, Inc. Mr. Oliveto was previously employed as a Chief Executive Officer & Director by Galleon Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Chelsea Therapeutics International Ltd., an Executive-in-Residence by A. M.
Pappas & Associates LLC, and a Director-Global Alliance by Hoffmann-La Roche, Inc. He received his undergraduate degree from Rutgers State University of New Jersey and an MBA from Rutgers State University of New Jersey.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/04/2026 | 446.244 ( 0,36 % ) | 633 666 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Director Ejecutivo | 07/03/2017 |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Director Ejecutivo | 07/03/2017 |
| Empresas | Cargo | Fin |
|---|---|---|
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Director Ejecutivo | 01/06/2016 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Director Ejecutivo | 23/06/2014 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Corporate Officer/Principal | 30/06/2008 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 01/01/2008 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 7 |
|---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Health Technology |
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Finance |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.